國藥控股(01099.HK)上半年歸母淨利下降2.67%至28.96億元
格隆匯 8 月 24日丨國藥控股(01099.HK)發佈2020年中期業績公告,報告期間,集團實現收入人民幣2037.65億元,同比增長1.04%;毛利為人民幣172.42億元,同比下降1.39%;實現溢利人民幣48.03億元,同比下降3.32%;實現母公司持有者應占溢利人民幣28.96億元,同比降低2.67%;基本每股盈利人民幣0.93元。
報告期內,集團累計實現銷售收入同比上升1.04個百分點,其中藥品分銷業務受疫情的影響相對較大,業務收入同比下降4.38%。而得益於集團戰略佈局和行業需求增長,醫藥零售和醫療器械板塊在疫情特殊時期顯示出了極強的韌性和增長潛力,兩個業務板塊在報告期內分別錄得約24.59%和23.59%的同比增長,集團業態佔比呈現進一步多元化趨勢。
回顧上半年,在中國百姓面臨新冠疫情重大風險的時候,集團勇擔風險和責任,以“醫藥行業國家隊”的使命感,憑藉自身高效的醫藥供應鏈體系全力保障疫區及全國各地的醫療物資供應,充分顯示了集團在面對重大突發衞生事件時的應急能力和經驗優勢。集團在此次抗擊疫情過程中的突出貢獻獲得了地方政府和各級醫療機構的高度讚揚,進一步提升了國藥控股的企業形象和品牌認可,鞏固了集團的業務網絡在全國醫療衞生供應鏈體系中的優勢地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.